Amarantus BioScience Holdings, Inc.

Equities

AMBS

US02300U2050

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:20:01 2024-04-23 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-80.00%

2022	Sector Update: Financial Stocks Still Adding to Wednesday Declines	MT
2020	Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	CI

Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries

January 11, 2019 at 05:00 am EST

Amarantus BioScience Holdings, Inc. and IDEA Pharma Ltd. announced a highly original partnership, to bring together Amarantus' innovative therapeutics and diagnostics portfolio with IDEA's path-to-market expertise. IDEA, who have supported 8 of the 15 biggest biopharmaceutical launches in the past 3 years, will partner with Amarantus in a novel royalty-split model. The virtual Chief Commercial Officer partnership will provide multi-year commercial strategy to the Amarantus portfolio of companies, with royalties paid to IDEA following successful monetisation. The Amarantus/IDEA Pharma partnership will run for 5 years, and be renewable upon mutual consent.

Latest news about Amarantus BioScience Holdings, Inc.

Sector Update: Financial Stocks Still Adding to Wednesday Declines	22-03-30	MT
Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	20-07-27	CI
Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.	20-01-29	CI
Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products	20-01-02	CI
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics	19-11-21	CI
Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc	19-10-24	CI
Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	19-10-23	CI
Amarantus Enters into Letter of Intent with the Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation	19-06-25	CI
Amarantus BioScience Holdings, Inc. Announces Positive Pre-Clinical Data for Manf in Wolfram Syndrome	19-06-18	CI
Amarantus Hires Evolution Venture Partners To Evaluate Alternatives For Expansion Into Legal Hemp	19-05-28	CI
Todos Medical Ltd. (OTCPK:TOMD.F) exercised the option to acquire the remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc..	19-04-21	CI
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries	19-01-11	CI
Todos Medical Ltd. Enters into Joint Venture Agreement with Amarantus to Develop Alzheimer’S Blood Diagnostic Lympro Test 2.0	18-12-03	CI
Coeptis Pharmaceuticals, Inc. entered into a binding agreement to acquire Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	18-11-27	CI
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test Vs. Amyloid Pet	18-05-04	CI
Amarantus Bioscience Holdings, Inc. Names Michael T. Ropacki as Chief Medical Advisor to Alzheimer's Blood Diagnostic LymPro Test Program	18-04-16	CI
Amarantus BioScience Holdings, Inc. (‘AMBS’) acquired certain assets of Avant Diagnostics, Inc. (‘Avant’) for $0.05 million.	18-04-05	CI
Amarantus BioScience Holdings, Inc. Announces Executive Changes	18-04-05	CI
Amarantus Bioscience Holdings, Inc. Announces Temporary Relocation of Headquarters to WeWork	18-04-02	CI
Amarantus BioScience Holdings, Inc. announced that it expects to receive $1.5 million in funding	18-02-25	CI
Amarantus Bioscience Holdings, Inc & MANF Therapeutics, Inc. Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF	17-12-14	CI
Amarantus Bioscience Holdings, Inc announced that it expects to receive $0.5 million in funding	17-11-16	CI
Amarantus Bioscience Holdings, Inc cancelled the acquisition of biomedical assets from SeD BioMedical Inc.	17-09-29	CI
Amarantus Bioscience Holdings, Inc Announces Resignation of Robert H. Trapp and Ronald Wei Resigned as Members of the Board of Directors	17-05-09	CI
Amarantus Bioscience Holdings, Inc. Establishes Two New Subsidiaries	17-04-17	CI

Chart Amarantus BioScience Holdings, Inc.

Duration

Period

Chart Amarantus BioScience Holdings, Inc.

More charts

Company Profile

Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. It has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Companyâs wholly owned subsidiary Cutanogen Corporation. The Companyâs wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AMARANTUS BIOSCIENCE HOLDINGS, INC.	-80.00%	630
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research